

**Oxtellar XR (oxcarbazepine ER)
Effective 12/1/2019**

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Oxtellar XR is long-acting formulation of oxcarbazepine and is FDA indicated for treatment of focal (partial) onset seizures in patients at least 6 years of age. Oxcarbazepine blocks voltage-sensitive sodium channels, stabilizing hyperexcited neuronal membranes, inhibiting repetitive firing, and decreasing the propagation of synaptic impulses. These actions are believed to prevent the spread of seizures. Oxcarbazepine also increases potassium conductance and modulate the activity of high-voltage activated calcium channels.

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Oxtellar XR excluding when the product is obtained as samples or via manufacturer’s patient assistance program.

OR

Authorization may be granted for members who meet all the following criteria and documentation has been submitted

1. The member has a diagnosis of epilepsy or a seizure disorder
2. The member is ≥ 6 years of age
3. Medical necessity for the branded extended-release formulation instead of oxcarbazepine tablets and suspension has been submitted **AND** one of the following:
 - The member has been stabilized on oxcarbazepine (any form)
 - The member has had an inadequate response or adverse reaction to any two anticonvulsants.

Limitations

1. Approvals may be granted for 36 months

References

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org



1. Oxtellar XR (oxcarbazepine) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals Inc; December 2018
2. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev 2009; :CD006453
3. Nevitt SJ, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev 2018; 10:CD003615

Review History

9/19/16 – Reviewed

9/18/17 – Reviewed

9/24/18 – Reviewed

9/18/19 – Added age requirement and medical necessity requirement for extended-release

09/16/20 – Reviewed at P&T

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.